• imatinib mesylate
  • The clinical trials on this list are studying Imatinib Mesylate. (cancer.gov)
  • This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. (cancer.gov)
  • Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (cancer.gov)
  • Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia. (cancer.gov)
  • Giving combination chemotherapy with, rituximab, mercaptopurine, pegaspargase, methotrexate, dasatinib and imatinib mesylate may be an effective treatment for acute lymphoblastic leukemia or lymphoblastic lymphoma. (cancer.gov)
  • This phase II trial studies how well dasatinib, nilotinib, and imatinib mesylate works in treating patients with newly diagnosed, previously untreated chronic myeloid leukemia in which fewer than 10% of the cells in the blood and bone marrow are blast cells (immature blood cells) (chronic phase). (cancer.gov)
  • powder
  • Eprosartan mesylate is a white to off-white free-flowing crystalline powder that is insoluble in water, freely soluble in ethanol, and melts between 248°C and 250°C. (rxlist.com)
  • salt
  • The chemical name is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide mesylate salt. (wikipedia.org)
  • Groups
  • Whereas mesylates are often hydrolytically labile, mesyl groups, when attached to nitrogen are robust with respect to hydrolysis. (wikipedia.org)